AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Discover the latest April 2025 update on Dow Dogs! Learn about top investment picks, forecasted gains, and market corrections ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now? During the ...

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

We recently published a list of Jim Cramer Recently Put These 10 Stocks Under Spotlight. In this article, we are going to ...

Merck & Co. Inc. closed 33.72% short of its 52-week high of $134.63, which the company achieved on June 25th.

Senator, Dr. Rasha Kelej, CEO of Merck Foundation and One of the Most Influential African Women for Six Consecutive Years ...

With the CSF-1R inhibitor space heating up, Germany's Merck Group has gone all-in on pimicotinib, paying Abbisko Therapeutics ...

Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.

Learn more about whether Corcept Therapeutics Incorporated or Merck & Co., Inc. is a better investment based on AAII's A+ ...